BACKGROUND: Cancer antigen 125 (CA-125) is a tumor marker used for the diagnosis and monitoring of ovarian carcinoma. It can also be elevated in endometriosis, inflammations, and in nongynecological malignancies. Up to date, serum CA-125 levels in inflammatory bowel diseases (IBD) have not been studied before. AIM: To assess the levels of CA-125 in patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS: Serum levels of CA-125 were investigated in 68 cases with UC (male/female: 47/21), 32 CD (male/female: 21/11), and 31 healthy controls (male/female: 16/15). Levels of CA-125 were also compared among UC patients according to lesion location, severity, and activity of CD. RESULTS: Serum CA-125 levels were 17.29+/-24.50 U/ml, 15.56+/-20.74 U/ml, and 8.85+/-2.62 U/ml in patients with UC, CD, and healthy controls, respectively. Serum CA-125 levels were significantly higher in UC compared to control group (P=0.001). Serum CA-125 levels were higher in CD patients compared to control group but there was no significance (P=0.087). Serum CA-125 levels were higher in pancolitis compared to distal type and left-sided UC. CONCLUSIONS: Our data suggest that serum CA-125 levels may be increased in patients with IBDs.
BACKGROUND:Cancer antigen 125 (CA-125) is a tumor marker used for the diagnosis and monitoring of ovarian carcinoma. It can also be elevated in endometriosis, inflammations, and in nongynecological malignancies. Up to date, serum CA-125 levels in inflammatory bowel diseases (IBD) have not been studied before. AIM: To assess the levels of CA-125 in patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS: Serum levels of CA-125 were investigated in 68 cases with UC (male/female: 47/21), 32 CD (male/female: 21/11), and 31 healthy controls (male/female: 16/15). Levels of CA-125 were also compared among UC patients according to lesion location, severity, and activity of CD. RESULTS: Serum CA-125 levels were 17.29+/-24.50 U/ml, 15.56+/-20.74 U/ml, and 8.85+/-2.62 U/ml in patients with UC, CD, and healthy controls, respectively. Serum CA-125 levels were significantly higher in UC compared to control group (P=0.001). Serum CA-125 levels were higher in CD patients compared to control group but there was no significance (P=0.087). Serum CA-125 levels were higher in pancolitis compared to distal type and left-sided UC. CONCLUSIONS: Our data suggest that serum CA-125 levels may be increased in patients with IBDs.
Authors: R Guimbaud; V Bertrand; L Chauvelot-Moachon; G Quartier; N Vidon; J P Giroud; D Couturier; S Chaussade Journal: Am J Gastroenterol Date: 1998-12 Impact factor: 10.864
Authors: A Bitton; M A Peppercorn; D A Antonioli; J L Niles; S Shah; A Bousvaros; B Ransil; G Wild; A Cohen; M D Edwardes; A C Stevens Journal: Gastroenterology Date: 2001-01 Impact factor: 22.682
Authors: Sunanda V Kane; William J Sandborn; Paul A Rufo; Anna Zholudev; James Boone; David Lyerly; Michael Camilleri; Stephen B Hanauer Journal: Am J Gastroenterol Date: 2003-06 Impact factor: 10.864
Authors: Babatunde O Akinwunmi; Ana Babic; Allison F Vitonis; Daniel W Cramer; Linda Titus; Shelley S Tworoger; Kathryn L Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-09-20 Impact factor: 4.254
Authors: Daniel W Cramer; Allison F Vitonis; William R Welch; Kathryn L Terry; Annekathryn Goodman; Bo R Rueda; Ross S Berkowitz Journal: Gynecol Oncol Date: 2010-09-17 Impact factor: 5.482
Authors: Barry H Smith; Lawrence S Gazda; Thomas J Fahey; Angelica Nazarian; Melissa A Laramore; Prithy Martis; Zoe P Andrada; Joanne Thomas; Tapan Parikh; Sudipta Sureshbabu; Nathaniel Berman; Allyson J Ocean; Richard D Hall; David J Wolf Journal: Chin J Cancer Res Date: 2018-02 Impact factor: 5.087